Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)

Population Health Research Institute202 enrolled

Overview

Recurrence is a common problem after catheter ablation for atrial fibrillation, affecting at least one out of three patients. Inflammation due to the procedure may contribute to pulmonary vein reconnection and, thus, failure of catheter ablation. This pilot study will assess whether a randomized, placebo-controlled, double-blind trial investigating a 10-day treatment with colchicine, a potent anti-inflammatory drug, to improve patient relevant outcomes after catheter ablation for atrial fibrillation is feasible.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

202

Conditions

Atrial Fibrillation Recurrence

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥ 18 years 2. Symptomatic atrial fibrillation and planned catheter-guided first or repeat ablation (pulmonary vein isolation) for atrial fibrillation (radiofrequency or cryoablation energy; concomitant ablation of the cavotricuspid isthmus and other lesions left at the discretion of the treating physician) 3. Written informed consent Exclusion Criteria: 1. Ablation for left atrial tachycardia or isthmus-dependent atrial flutter only (i.e. without pulmonary vein isolation) 2. Administration of a strong inhibitor of CYP3A4 or p-gp (clarithromycin, erythromycin, telithromycin, cyclosporine, ketoconazole or itraconazole) 3. Known hypersensitivity to colchicine 4. Serious gastrointestinal disease (severe gastritis or diarrhea) 5. Clinically overt hepatic disease 6. Severe renal disease (eGFR\< 30ml/min/1.73m2) 7. Clinically significant blood dyscrasia (e.g., myelodysplasia) 8. Absolute indication for or ongoing treatment with colchicine 9. Pregnant or breastfeeding women, or women of child-bearing potential who do not use a highly effective form of birth control

Outcomes

Primary Outcomes

Average monthly enrollment rate

Average number of patients enrolled per month

Time frame: Through study completion (enrollment phase estimated to last 18 months, total study duration estimated to last 24 months)

Compliance with study treatment

Number of provided capsules taken (measured as a proportion of 20 capsules)

Time frame: From randomization until 10 days after catheter ablation

Rate of complete follow-up at 6 months

This will describe the rate of patients for whom the 6-month follow visit can be completed

Time frame: From inception until completion of the study

Secondary Outcomes

Rate of non-infectious diarrhea

Three or more loose stools per day, in absence of an overt infectious cause

Time frame: From randomization until 10 days after catheter ablation

Rate of signs and symptoms of pericarditis

Evidence of new or worsening pericardial effusion on echocardiogram, friction rub on auscultation or pleuritic chest pain

Time frame: From randomization until 10 days after catheter ablation

Recurrence of atrial fibrillation within the first 2 weeks after catheter ablation

Any episode of atrial fibrillation lasting \> 30 seconds within 2 weeks after catheter ablation for atrial fibrillation. Atrial flutter or other forms of atrial tachycardia are included in this definition

Time frame: From randomization until 2 weeks after catheter ablation for atrial fibrillation

Recurrence of atrial fibrillation between 10-15 weeks after catheter ablation

Any episode of atrial fibrillation lasting \> 30 seconds between 10-15 weeks after catheter ablation for atrial fibrillation. Atrial flutter or other forms of atrial tachycardia are included in this definition

Time frame: Between week 10 and 15 after catheter ablation for atrial fibrillation

Rate of patients with composite clinical endpoint

Emergency department visit: Patient seeking medical attention at any emergency department or Hospitalization for cardiovascular cause: Minimum of one overnight stay in hospital for cardiovascular reason (e.g. recurrence of atrial fibrillation, atrial flutter, atrial tachycardia; hypotension; hypertension; heart failure; myocardial infarction; bleeding, stroke etc.) or Cardioversion: Pharmacological or electrical attempt of or restoring sinus rhythm, irrespective of success of the procedure or Repeat ablation for atrial fibrillation, atrial flutter or left atrial tachycardia: Catheter-guided pulmonary vein isolation, or ablation of cavotricuspid isthmus, or ablation for other left atrial tachycardia (e.g. macro-reentrant tachycardia, focal tachycardia) after the index procedure

Time frame: Through study completion (estimated to be up to 24 months)

Rate of all-cause mortality

This will describe the rate of all-cause mortality during the course of the study.

Time frame: Through study completion (estimated to be up to 24 months)

Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes